Wegovy 0.5mg FlexTouch Solution For Injection 1.5ml
In Stock • people bought this
- Supports weight loss with semaglutide
- Enhances appetite suppression effectively
- Improves metabolic and cardiovascular health
- Promotes sustainable weight control
Delivery : 2-4 days PAN India
Seller : Davadost pharma private limited
Discover the Benefits of ABHA Card registration
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHAIntroduction to
Wegovy 0.5mg FlexTouch Solution For Injection is a prescription weight-loss injectable that contains semaglutide, part of the GLP‑1 receptor agonist class. Intended as a stepping-stone in the dose escalation process, the 0.5 mg strength follows the initial 0.25 mg starter. Combined with a reduced-calorie diet and regular physical activity, this injection supports individuals with obesity (BMI ≥ 30) or overweight (BMI ≥ 27 with related health conditions) in their journey towards sustainable health goals.
Semaglutide mimics the glucagon-like peptide-1 hormone, which naturally signals fullness to the brain and slows digestion—leading to lower calorie intake. Clinical studies outline that users progressively lose weight as the dose increases, eventually reaching maintenance doses (1.7–2.4 mg). The 0.5 mg dose is often reached after the first month, striking a balance between effectiveness and tolerability.
Semaglutide acts by mimicking the body's GLP‑1 hormone, which regulates appetite and digestion. It binds to brain receptors, reducing hunger and helping control food intake. Meanwhile, it slows gastric emptying, promoting more prolonged feelings of fullness. It also improves glucose metabolism by boosting insulin secretion and suppressing glucagon, aiding in blood sugar stabilization . These mechanisms combine to lower daily calorie consumption and optimize metabolic health. In STEP clinical trials, patients gradually dose-escalated semaglutide over several months and achieved average weight losses of 10–15%, making weight control more attainable and sustainable.
- Begin at 0.25 mg once weekly for 4 weeks.
- Follow-up dose: 0.5 mg once weekly—this is the dose discussed here.
- Inject subcutaneously (under the skin) into the thighs, abdomen, or upper arm—rotate sites each time.
- Administer on the same day each week, with or without food.
- Increase the dose every 4 weeks until reaching maintenance levels (1.7–2.4 mg) as directed by your physician.
- Do not use if you have a personal/family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Inform your doctor if you’ve experienced pancreatitis or have severe gastrointestinal disorders.
- Before surgery, caution is advised because slowed gastric emptying could raise aspiration risk during anesthesia.
- In patients with diabetic retinopathy, ongoing monitoring is necessary—rapid weight loss may temporarily worsen eye conditions.
- Sustained weight loss: Clinical studies report average reductions of 10–15% body weight with maintenance doses.
- Appetite regulation: Reduced hunger and smaller portion sizes lead to lower caloric intake.
- Cardiovascular protection: Approved to reduce heart attack, stroke, and cardiovascular death risks in obese/m overweight individuals with existing heart disease.
- Better blood sugar control: Enhanced insulin response and lower glucose production help manage or prevent Type 2 diabetes.
- Improved metabolic markers: Secondary benefits may include lower blood pressure and better cholesterol levels due to weight loss.
- Gastrointestinal issues: nausea, vomiting, diarrhea, constipation, abdominal discomfort
- Metabolic: hypoglycemia in individuals on insulin/sulfonylureas
- Other: headache, fatigue, dizziness
- Less frequent but serious side effects may include pancreatitis, gallbladder disease, injection-site reactions, temporary worsening of diabetic retinopathy, and thyroid C-cell tumors (noted in rodent studies, though relevance to humans is uncertain).
- If you miss a dose of Wegovy and your next scheduled dose is more than 48 hours away, take the missed dose as soon as you remember.
- If your next dose is due in less than 48 hours, skip the missed dose and take the next one as scheduled.
- If you have missed doses for more than 2 weeks, resume your treatment on your regular dosing day or consult your healthcare provider for guidance on restarting.
Health And Lifestyle
- Insulin and sulfonylureas (e.g., glimepiride, glipizide): increased risk of hypoglycemia; dose adjustments required.
- ACE inhibitors (e.g., lisinopril, ramipril): potential for amplified low blood sugar episodes.
- Other GLP‑1 agonists (Ozempic, Rybelsus): insure not on multiple semaglutide-based meds.
- Alcohol: May amplify dehydration, nausea, dizziness, and risk of pancreatitis.
- Green tea & garlic supplements: May intensify hypoglycemic effects.
- High-fiber meals: May slow absorption—consistent diet aids steady performance.
Obesity and overweight increase risks for Type 2 diabetes, hypertension, cardiovascular events, and non-alcoholic fatty liver disease (NAFLD). Wegovy addresses these conditions by reducing appetite, promoting weight loss, improving metabolism, and lowering heart-related complications—a holistic approach to health beyond just shedding pounds .
Safety Advice For
- High risk
- Moderate risk
- Safe
No direct liver toxicity exists, but dehydration may impair liver function. Use cautiously if liver disease is present.
Diarrhea, vomiting, or nausea can cause dehydration, stressing kidneys. Monitor fluid intake, especially if you have pre-existing kidney ailments.
No direct interactions have been found, but alcohol may amplify nausea, dizziness, and dehydration—common side effects of GLP‑1 drugs.
Low blood sugar, dizziness, or fatigue may occur—especially if used with insulin or sulfonylureas. Pause driving or operating machinery until you’re sure how Wegovy affects you.
Semaglutide crosses over to cause fetal harm in animal models; human safety isn’t established .
Semaglutide is found in animal milk; its effects on infants are unknown. It’s best avoided during lactation.
- Ramp up slowly — gives your body time to adapt, reducing side effects. Stick to weekly schedule — helps maintain consistent efficacy. Rotate injection spots — avoids irritation and ensures full absorption. Weigh-in regularly — helps track progress and guide dosage decisions. Stay flexible with eating habits to manage side effects like nausea or reflux.
- Generic Name: Semaglutide
- Brand and Strength: Wegovy 0.5 mg
- Drug Class: GLP‑1 receptor agonist
- Administration: Once-weekly subcutaneous injection
- Indications: Long-term weight management, Cardiovascular risk reduction in obese or overweight adults with heart disease
Store Wegovy pens between 2–8 °C (refrigerator). Once opened, keep at room temperature (≤ 30 °C) for up to 28 days. Keep the pen cap on to protect from light. Discard needles in approved sharps containers. Do not freeze or expose to heat beyond 30 °C.
- Weeks 1–4: 0.25 mg weekly. Weeks 5–8: 0.5 mg weekly. Weeks 9–12: Increase to 1.0 mg weekly; further escalate every 4 weeks up to 2.4 mg as tolerated. Your healthcare provider may adjust the schedule based on your response and side effect profile.
Wegovy 0.5mg FlexTouch Solution For Injection is a pivotal mid-level dose in the semaglutide-based treatment regimen, helping to amplify appetite suppression and weight-loss momentum. By engaging the GLP‑1 pathways, it delivers metabolic and cardiovascular improvements. Paired with healthy lifestyle habits and mindful monitoring, it’s a powerful option for sustainable weight control under medical guidance.
1. Why is Wegovy started at lower doses?
2. When can I expect to lose weight on 0.5 mg?
3. Is 0.5 mg effective long-term?
4. Can I switch injection days?
5. What should I do about injection pain?
6. Will it make me dizzy when driving?
7. Can Wegovy cause hair loss?
8. Can I take other GLP‑1 drugs with Wegovy?
9. Do I need monitoring during treatment?
10. Will I regain weight after stopping Wegovy?
Written By
Priyanka Sonkushre
Content Updated on
Tuesday, 24 March, 2026
